Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985090 | 0.84 | ALDH1A1 (0.50) | MAPTGABRA2GABRB2ALDH1A1HPGD | |
| SCHEMBL14188927 | 0.84 | ALDH1A1 (0.51) | MAPTALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL23147153 | 0.78 | BAZ2B (0.67) | MAPTALDH1A1HPGDKMT2ATSHR | |
| SCHEMBL14215926 | 0.76 | ALDH1A1 (0.50) | MAPTALDH1A1HPGDKMT2ALMNA | |
| SCHEMBL12494435 | 0.75 | CYP1A2 (0.57) | MAPTALDH1A1HPGDKMT2ATDP1 | |
| SCHEMBL3410900 | 0.75 | GABRA2 (0.54) | MAPTGABRA2GABRB2ALDH1A1HPGD | |
| SCHEMBL679127 | 0.75 | MAPT (0.61) | MAPTGABRA2GABRB2ALDH1A1HPGD | |
| SCHEMBL11308735 | 0.74 | ALDH1A1 (0.54) | MAPTGABRA2GABRB2ALDH1A1HPGD | |
| SCHEMBL4986987 | 0.74 | FGFR1 (0.53) | MAPTALDH1A1HPGDTSHRLMNA | |
| SCHEMBL28806864 | 0.73 | NR4A2 (0.72) | MAPTGABRA2GABRB2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1847535-A1 | 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119518-A1 | 1-(Piperidin-4- Yl)-1H-Indole Derivatives | TPH1, HTR1D, HTR1B | MAPT 1563/4885GABRA2 2403/4885GABRB2 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.